Icecure Medical Ltd Ord (ICCM) Stock Price, Quote & News

Company Profile

IceCure Medical Ltd, a commercial-stage medical device company, engages in the research, development, and marketing of cryoablation systems, disposables, and technologies for treating tumors in the United States, Japan, India, China, Israel, and internationally. The company offers the ProSense system, a single probe cryoablation system for the treatment of malignant breast tumors, as well as its associated disposables, including CryoProbes needles, and guiding needles/introducers; and IceSense3...

Industry: Medical Devices

Sector: Healthcare

Phone: 972 4 623 0333

Fax: 972 4 623 0222

Website: www.icecure-medical.com

Address:

7 Ha’Eshel St., PO Box 3163, Caesarea, Israel

noonknight Apr. 17 at 12:28 AM

$ICCM The facts are that we don't know what ICCM is, or is not doing. There could be bigger things happening right now. Or not right now, but later. We don't know what is going on in great detail, but that's the market. All is not transparent, until it is.

0 · Reply

Socaldodgerfan8 Apr. 16 at 9:07 PM

$ICCM Only $.6368 to go! #wecandothis!

0 · Reply

guytfcdyj Apr. 14 at 2:57 PM

$ICCM Everyone forget this stock. No concern, no rise.

0 · Reply

VlaDracula Apr. 8 at 10:16 PM

$ICCM they don’t lobbying, I have not heard them lobbying an approved product which is a sign of weak leadership, they can lobby it for improvement with funding on lower the minimum required age group or acquisition of iccm, but they don’t, and they are Jewish, shouldn’t they have more connections to big pharmaceuticals?

1 · Reply

grandpa_dirt Apr. 8 at 6:09 PM

$ICCM I'm just hoping they can get a 6 month extension without doing a r/s. Seems like they could show steady growth in sales over the next 2 quarters as a means to get above the 1.00 stock minimum and in turn 50 million market cap by end of year. I don't expect that to happen, but I can hope.

1 · Reply

Shanenobody Apr. 7 at 7:47 PM

$ICCM Any idea why this is moving today?

1 · Reply

prismmarketview Apr. 7 at 4:13 PM

PRISM Mid-Day Movers: Cybersecurity and NextGen Tech & AI are leading today. HUB Cyber Security Ltd. ( $HUBC) is up about 60% as traders pile in following its balance-sheet overhaul and reverse split. The sub-$15M market cap and high volatility mean moves can be sharp and short-lived. Predictive Oncology Inc. ( $POAI.X) is up roughly 32% as speculative money returns to the ultra-small-cap AI drug discovery play, where limited float keeps price action highly momentum-driven. Other Notable Movers: Quince Therapeutics ( $QNCX) up 23% IceCure Medical ( $ICCM) up 19% Mullen Automotive ( $MULN.X) down -19% https://prismmarketview.com/prism-mid-day-movers-cybersecurity-and-nextgen-tech-ai-are-leading-today/

0 · Reply

Bernperez Apr. 3 at 2:57 PM

$ICCM It is. It was approved there before the US. The US was the FDA approval. It's used more in other countries. The problem is people who run the company don't know what they're doing in marketing and business wise. No foward plan for partnering, or marketing. Not covered by insurance. I've been following this company for 2 years. US FDA approval took a year from filing. The people running this company had a year to come up with a plan. Lobby insurance companies, hospitals, and investors. The people running this company are idiots. The only stock I've ever seen not move and go down after FDA approval. Good luck with this one. Thank god I averaged down and not loose that much. I'm out!!! I'm out!!!

0 · Reply

noonknight Mar. 31 at 11:07 PM

$ICCM The US isn't the only market. One would think that this new tech would be better accepted and better used in Europe. What gives...?

2 · Reply

noonknight Mar. 31 at 11:04 PM

$ICCM From Bard AI: Switzerland: In November 2025, ProSense® received regulatory approval in Switzerland for the treatment of both malignant and benign tumors in the breast, lung, liver, and kidney. Notably, the Swiss approval is broader than the U.S. version, as it is not strictly limited by a specific age "floor" like the 70+ requirement in the U.S. European Union: The system is currently marketed and sold in several EU countries. Under the CE Mark, it is generally approved for the "ablation of cancerous and benign tumors," which allows physicians more clinical discretion in patient selection across various age groups, provided the clinical criteria (like tumor size and type) are met. China: The system has previously received clearance from the NMPA (National Medical Products Administration) for broader indications, including benign breast tumors (fibroadenomas). see next post....

1 · Reply

IceCure Announces Pricing of $4.0 Million Registered Direct Offering and Concurrent Private Placement

Mar 25, 2026, 8:30 AM EDT - 25 days ago

IceCure Reports Positive 5-Year Top-Line Results from ICESECRET Kidney Cancer Cryoablation Study: 89.4% and 83.9% Recurrence-Free Rates

Mar 24, 2026, 8:30 AM EDT - 26 days ago

IceCure Appoints Meir Peleg as Chief Financial Officer

Mar 17, 2026, 8:30 AM EDT - 4 weeks ago

IceCure Reports 2025 Full Year Financial & Operational Results

Mar 11, 2026, 8:30 AM EDT - 5 weeks ago

U.S. FDA Approves IceCure's Post-Marketing "ChoICE" Study for ProSense® Cryoablation in the Local Treatment of Low-Risk Breast Cancer

Mar 10, 2026, 8:30 AM EDT - 5 weeks ago

IceCure Medical to Report 2025 Full Year Financial and Operating Results on March 17, 2026

Mar 9, 2026, 8:30 AM EDT - 5 weeks ago

American Society of Breast Surgeons (ASBrS) Resource Guide Update Recommends Cryoablation for Low-Risk Breast Cancer

Mar 2, 2026, 8:30 AM EST - 6 weeks ago

IceCure Medical Reports Independent Study Published in PLOS One Demonstrating ProSense® Cryoablation Safe and Effective in Treatment of Breast Fibroadenomas

Feb 23, 2026, 8:30 AM EST - 7 weeks ago

IceCure Medical Successfully Completes 5-Year Patient Follow Up in ICESECRET Kidney Cancer Cryoablation Study: Final Analysis Expected in Second Quarter of 2026

Feb 19, 2026, 8:30 AM EST - 2 months ago

IceCure Announces Thomas Hospital of Infirmary Health Installs ProSense®, Becomes First Hospital in Alabama to Offer Breast Cancer Cryoablation

Feb 11, 2026, 8:30 AM EST - 2 months ago

IceCure Announces Shero Imaging is First to Offer Breast Cancer Cryoablation Procedures in Missouri with ProSense®

Feb 9, 2026, 4:30 PM EST - 2 months ago

IceCure Announces Planned Departure of CFO Following Nine Years of Service and Key Milestones Achieved

Jan 28, 2026, 8:30 AM EST - 2 months ago

IceCure Celebrates American Society of Breast Surgeons' (ASBrS) Proposed Breast Cancer Treatment Guidelines Which Include Cryoablation for Low-Risk Breast Cancer

Jan 12, 2026, 8:30 AM EST - 3 months ago

IceCure CEO Issues Letter to Shareholders: Reports Record Fourth Quarter and Full Year 2025 ProSense® Sales

Dec 17, 2025, 8:30 AM EST - 4 months ago

IceCure Expected to Report Record Fourth Quarter Sales in North America Driven by Recent FDA Clearance of ProSense® Cryoablation for Low-Risk Breast Cancer

Dec 10, 2025, 8:30 AM EST - 4 months ago

IceCure's ProSense® Cryoablation Featured in 4 Independent Breast Cancer Studies Presented at Radiological Society of America 2025 Annual Meeting

Dec 5, 2025, 8:30 AM EST - 4 months ago

IceCure Receives Notice of Patent Allowance in China for a Novel Cryogen Flow Control to Optimize Patient Cryoablation Outcomes

Nov 19, 2025, 8:54 AM EST - 5 months ago

IceCure Reports Financial & Operational Results for the Nine Months Ended September 30, 2025

Nov 18, 2025, 8:30 AM EST - 5 months ago

IceCure's ProSense® Cryoablation System Receives Regulatory Approval in Switzerland for Indications Including Breast, Lung, Liver, and Kidney Cancer

Nov 14, 2025, 4:30 PM EST - 5 months ago

IceCure Medical Announces Receipt of Nasdaq Minimum Bid Price Notification

Nov 12, 2025, 8:30 AM EST - 5 months ago

IceCure Medical to Report Third Quarter 2025 Financial and Operating Results on November 19, 2025

Nov 10, 2025, 8:30 AM EST - 5 months ago

IceCure Promotes Shay Levav to Chief Operating Officer as Company Ramps up for Increased Commercial Traction

Nov 3, 2025, 8:30 AM EST - 5 months ago

IceCure's Cryoablation System Combined with Radiation Therapy Successfully Treats Non-Small Cell Lung Cancer (NSCLC) with 92% Disease-Specific 5-year Survival

Oct 13, 2025, 8:30 AM EDT - 6 months ago

IceCure's ProSense® Showcased at TME Fall Summit: "Take the Lead in Breast Cancer Care" Roundtable Highlighting Cryoablation Advances

Oct 9, 2025, 8:30 AM EDT - 6 months ago

IceCure Medical to Attend the 2025 Maxim Growth Summit

Oct 3, 2025, 12:28 PM EDT - 7 months ago

IceCure Medical's ProSense® Cryoablation Granted FDA Marketing Authorization for Treatment of Low-Risk Breast Cancer in Women Aged 70 and Above: Significant Development in Giving Women with Breast Cancer Minimally Invasive Care

Oct 3, 2025, 12:19 PM EDT - 7 months ago

IceCure Receives FDA Marketing Authorization for ProSense® Cryoablation for the Treatment of Low-Risk Breast Cancer in Women Aged 70 and Above

Sep 30, 2025, 8:30 AM EDT - 7 months ago

IceCure's ProSense® at the European Society of Breast Imaging Congress 2025: Unlocking De-Escalation of Care in Breast Cancer, Positive Results from 5 Independent Studies Presented

Sep 22, 2025, 8:30 AM EDT - 7 months ago

IceCure's ProSense® Featured at CIRSE 2025 Annual Meeting: Positive Clinical Results with Cryoablation from 4 Independent Studies Presented

Sep 18, 2025, 8:30 AM EDT - 7 months ago

IceCure Granted Notice of Allowance for U.S. Patent for its Next-Generation XSense™ Cryoprobes

Sep 15, 2025, 8:30 AM EDT - 7 months ago

IceCure Receives Regulatory Approval in Israel for its Next-Generation XSense™ Cryoablation System for Breast Cancer and Other Indications

Sep 8, 2025, 8:30 AM EDT - 7 months ago

Two New Publications from the Independent THERMAC Trial Featuring IceCure's ProSense® in Breast Cancer Finds 95% of Patients Satisfied with Thermal Ablation; ProSense® Cryoablation Achieves Highest Complete Ablation Rate

Sep 4, 2025, 8:30 AM EDT - 8 months ago

IceCure's ProSense® Substantially Reduces Abdominal Wall Endometriosis Pain with High Procedural Efficacy

Aug 13, 2025, 8:30 AM EDT - 8 months ago

IceCure Reports Financial & Operational Results for the First Half of 2025

Aug 6, 2025, 8:30 AM EDT - 9 months ago

IceCure to Report First Half 2025 Financial and Operating Results on August 13, 2025

Jul 29, 2025, 9:00 AM EDT - 9 months ago

IceCure Announces Expiration and Results of Approximately Two Times Over-Subscribed Rights Offering for Aggregate Gross Proceeds of $10.0 Million

Jul 25, 2025, 9:00 AM EDT - 9 months ago

IceCure's ProSense® Featured at Japanese Breast Cancer Society Conference: Updated Positive Clinical Data Shows 99% Recurrence Free Rate with Cryoablation

Jul 24, 2025, 9:00 AM EDT - 9 months ago

IceCure Reminds Shareholders of Upcoming Expiration of Rights Offering Subscription Period

Jul 10, 2025, 8:00 AM EDT - 10 months ago

IceCure Announces Commencement of Rights Offering

Jul 3, 2025, 8:30 AM EDT - 10 months ago

IceCure Reports Preliminary Financial Results for the Three and Six Months Ended June 30, 2025

Jun 25, 2025, 9:23 AM EDT - 10 months ago

IceCure Announces Record Date for Rights Offering for Up to $10 Million

Jun 9, 2025, 8:30 AM EDT - 11 months ago

IceCure Receives Notice of Patent Allowance in U.S. for a Novel Cryogen Flow Control to Optimize Patient Outcomes

May 28, 2025, 8:30 AM EDT - 11 months ago

IceCure Medical Reports First Quarter 2025 Financial Results

May 21, 2025, 8:30 AM EDT - 11 months ago

IceCure to Report First Quarter 2025 Financial & Operational Results on May 28, 2025

May 6, 2025, 8:30 AM EDT - 1 year ago

IceCure Receives High Level of Interest from Breast Surgeons at ASBrS 2025 Annual Meeting Following Recent Positive FDA Development on ProSense® Cryoablation

Apr 30, 2025, 8:30 AM EDT - 1 year ago

IceCure Announces Positive FDA Development: Understanding on Path Forward for Marketing Authorization of ProSense® Cryoablation in Women 70+ with Early-Stage Breast Cancer

Apr 28, 2025, 8:30 AM EDT - 1 year ago

IceCure Exhibits ProSense® & Sponsors Breast Cryoablation Courses at the Society of Breast Imaging Symposium

Apr 22, 2025, 8:30 AM EDT - 1 year ago

IceCure's ProSense® Featured at European Conference on Interventional Oncology with an Emphasis on Breast Cancer Cryoablation

Mar 27, 2025, 8:30 AM EDT - 1 year ago

IceCure Medical Reports 2024 Financial Results: 42% Growth in ProSense® Cryoablation Sales in North America

Mar 24, 2025, 8:30 AM EDT - 1 year ago

IceCure's ICESECRET Kidney Cancer Cryoablation Study Interim Results Presented at European Association of Urology Conference in Spain: 88.7% Recurrence-Free Rate

noonknight Apr. 17 at 12:28 AM

0 · Reply

Socaldodgerfan8 Apr. 16 at 9:07 PM

$ICCM Only $.6368 to go! #wecandothis!

0 · Reply

guytfcdyj Apr. 14 at 2:57 PM

$ICCM Everyone forget this stock. No concern, no rise.

0 · Reply

VlaDracula Apr. 8 at 10:16 PM

1 · Reply

grandpa_dirt Apr. 8 at 6:09 PM

1 · Reply

Shanenobody Apr. 7 at 7:47 PM

$ICCM Any idea why this is moving today?

1 · Reply

prismmarketview Apr. 7 at 4:13 PM

0 · Reply

Bernperez Apr. 3 at 2:57 PM

0 · Reply

noonknight Mar. 31 at 11:07 PM

$ICCM The US isn't the only market. One would think that this new tech would be better accepted and better used in Europe. What gives...?

2 · Reply

noonknight Mar. 31 at 11:04 PM

1 · Reply

Bernperez Mar. 31 at 11:38 AM

$ICCM take it from someone following this company for over 2 years. The product and technology is great and works better than anything out there!!! The best results in cancer treatments!!! It's the management and people running this company. They suck!! You would think they had a plan once they got their approvals around the world, but they didn't. A plan foward, a plan to market, but they didn't. A partnership with a company that can take them to the next stage, level. No such planning. This company should be trading at around $10 but it's not because of the idiots running the company. Get out!!! I did.

1 · Reply

StStephen72 Mar. 31 at 1:26 AM

$ICCM Crikey. This bites. Damnit I should have sold the rest at a loss when I sold my green layers. Wasn't expecting it this bad. But literally my entire watch list is red today and my accounts only green is the cover class I sold against some core positions. Probably let some of them ride to expiration and buy to close a few of them if this chit continues. Feeling poor again. Pete

0 · Reply

Socaldodgerfan8 Mar. 30 at 8:04 PM

$ICCM Getting raw-dogged right now.

0 · Reply

VikingTrade Mar. 30 at 5:18 PM

$ICCM this is why Maxim wasn’t allowed to talk. They knew this was coming

1 · Reply

VlaDracula Mar. 30 at 4:51 PM

$ICCM The majority of breast cancer cases—and therefore surgeries—occur in women between ages 50 and 70. ICCM is regulated to 70 and above. That’s the problem.

0 · Reply

VlaDracula Mar. 30 at 4:48 PM

$ICCM they actually have a good result of data but a bad regulation policy for the age requirement to have the surgery done their way, if the age is 55 and above then this will be a different story of sp

0 · Reply

Biorocksme Mar. 30 at 4:46 PM

$ICCM flushing reverse split obviously

0 · Reply

prismmarketview Mar. 30 at 4:35 PM

PRISM Mid-Day Movers: Healthcare and Aerospace & Defense are Today's Leaders. Bullfrog AI Holdings (NASDAQ: $BFRG) is ripping higher, up about 126% on a massive volume spike as this ultra‑low‑float, AI‑driven drug discovery micro‑cap becomes a momentum target in high‑risk territory. Astrotech (NASDAQ: $ASTC) is also soaring, recently up roughly 115–120% as heavy volume re‑rates the ultra‑thin micro‑cap off its lows despite a sub‑$10M market cap, negative EPS and a history of sharp volatility. Other Notable Movers: Iterum Therapeutics plc ($ITRM) up 75% Hepion Pharmaceuticals ( $HEPA) up 19% IceCure Medical ( $ICCM) down -22%

0 · Reply

Lstreak Mar. 30 at 4:01 PM

$ICCM New low of .2771 so far the inevitable stock split looks like it's coming sooner than later.

0 · Reply

Logan93 Mar. 30 at 3:31 PM

$ICCM They need to get the reverse split out of the way or they’re just going to pound it down to a nickel. There’s high insider ownership here so they’re just shooting themselves in the foot by delaying the inevitable. I wouldn’t be holding this right now.

0 · Reply

Lirik Mar. 30 at 12:33 AM

$ICCM the latest 4 million dollar raise/dilution wasn’t enough. They need 10x that with their current employee count of 70 and to pay for research requirements. The only good news is they have made some deals with the largest hospital chains in the US. Sales will be increasing drastically quarter to quarter but will it be enough to move the share price significantly?

0 · Reply

Logan93 Mar. 27 at 3:26 PM

$ICCM “According to the Notice, the Company has until May 11, 2026, to regain compliance with the minimum bid price requirement.” From 11/14 press release. Question is do they go for another 180-days or reverse split before the deadline? I honestly don’t see a path for them to close above a buck for ten consecutive days by May 11th.

1 · Reply

Market Cap	29.14M
Revenue (ttm)	3.38M
Net Income (ttm)	-15.06M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-445.56%
Debt to Equity Ratio	0.00

Volume	217,600
Avg Vol	493,544
Day's Range	N/A - N/A
Shares Out	81.18M
Stochastic %K	84%
Beta	0.52
Analysts	Strong Sell
Price Target	$2.78